Disease control and safety in relapsing remitting multiple sclerosis (RRMS) patients switching from natalizumab to fingolimod: A 32-week, rater-and patient-blind, randomized, parallel-group study (TOFINGO)

Authors
Category Primary study
JournalMultiple Sclerosis
Year 2013
This article has no abstract
Epistemonikos ID: 9d2398f8bb89e8e975ef4712c0d6effb953b256e
First added on: Nov 18, 2025